Thrombolex and Aidoc Form Strategic Partnership for RAPID-PE Registry Enrollment

July 30, 2024—Thrombolex, Inc. and Aidoc recently announced a strategic partnership focused on the treatment of acute pulmonary embolism (PE). The collaboration will leverage Aidoc’s artificial intelligence (AI) technology to accelerate patient identification and enrollment for Thrombolex’s RAPID-PE study.

According to the companies, RAPID-PE is a prospective, single-arm, multicenter, postmarket clinical registry evaluating the efficacy and safety of Thrombolex’s Bashir endovascular catheters in the treatment of acute intermediate-risk PE. The RAPID-PE clinical study is currently qualifying multiple centers across the United States.

The study’s therapy protocol includes a single-session treatment (< 1 hour) with no need for an intensive care unit (ICU) stay and a reduced dose of lytics (4 mg per pulmonary artery). By avoiding prolonged ICU stays, patients can experience faster recovery times and return to their daily lives sooner, noted the press release.

The companies stated that Bashir catheters are intended to immediately restore blood flow, rapidly resolve blood clots, and help reduce complications. Aidoc’s AI capabilities and tailored mobile application will provide local health care teams at RAPID-PE trial sites with timely alerts on patients who meet the inclusion criteria and promote a seamless workflow.

Aidoc’s technology features dedicated FDA-cleared algorithms for PE, central PE, incidental PE, and right ventricle/left ventricle ratio. It also alerts care teams to both expected and unexpected PE cases for faster triage and coordination with the right specialists.

Recent studies showed the mean hospital length of stay decreased by 36.7% and the annual volume of patients referred for interventional therapies rose by 68% compared to the period before the implementation of Aidoc PE AI, advised the companies.

“Combining Thrombolex’s innovative pharmacomechanical technology with Aidoc’s advanced AI-powered imaging solutions enhances speed to diagnosis and treatment efficiency for acute PE patients,” commented RAPID-PE co-national physician investigator Wissam Jaber, MD, in the press release. “This collaboration, along with RAPID-PE’s groundbreaking single session investigational protocol, represents a major step forward in improving patient outcomes and advancing the standard of care in our field.”